-
Intra-epidermal Nerve Fibers Density and Nociception in EPO-Treated Type 1 Diabetic Rats with Peripheral Neuropathy
Time of Update: 2020-12-19
Small-diameter nerve fibers, which subserve nociception, can be affected early in peripheral neuropathies, although theirinjury may not be detectable by routine neurophysiologic tests. On the other hand, skin biopsy has proved
-
Evaluating Effects of EPO in Rodent Behavioral Assays Related to Depression
Time of Update: 2020-12-05
Rodent behavioral models that areresponsive to clinically used antidepressants as well as to neurotrophic compounds can be used to assess potential antidepressantproperties of EPO and EPO-like compounds.
-
Brain Ischemic Injury in Rodents: The Protective Effect of EPO
Time of Update: 2020-12-04
Those models allow evaluating the efficiency of therapeuticstrategy of ischemia from tissular aspect to behavioral and cognitive impairment assessment.
-
The European Patent Office (EPO) has granted CRISPR-Cas9 a patent title.
Time of Update: 2020-09-08
. Cook-Deegan has long argued that the University of California and the Broad Institute use cross-patent licensing to enable patent sharing to provide the best environment for CRISPR or the billions of dollars in pharmaceutical value
-
Concord fermentation Kirin long-lasting EPO "Dayipotin alpha injection" approved in China
Time of Update: 2020-07-11
The international EPO market is dominated by Daipotin alpha, a drug developed jointly by Amin/Concord Fermented Kirin and approved by the FDA for listing in September 2001.
-
Another long-lasting EPO was approved in the domestic EPO market competition is becoming more intense
Time of Update: 2020-07-09
Wen-Dopine recently, Concord Fermentation Kirin Co., Ltd. Dayipotin alpha injection application (JXSS190005/6/7/8/9) in the NMPA status changed to "in approval", which means that another long-acting EPO drug will soon be approved in China.
-
Blood: Anti-BMP6 antibody combined with EPO to treat chronic anemia!
Time of Update: 2020-06-24
in addition to offsetting the iron limits of hepaparin-driven red blood cell generation, the researchers also found that KY1070 and recombinant human EPO combination therapy improved red blood cell response qualitatively and quantitatively compared to monotherapy.
-
Blood: Macrophage Epo receptor signals promote red line differentiation during stress-forming
Time of Update: 2020-06-24
Epo signals in macrophages induce lipid media to promote stressed red blood cell progenitor cell differentiation.
-
Another long-lasting EPO was approved in the domestic EPO market competition is becoming more intense
Time of Update: 2020-06-17
Recently, Concord Fermentation Kirin Co., Ltd. Dayibotin alpha injection application (JXSS190005/6/7/8/9) in nMPA status changed to "in approval", which means that another long-acting EPO drug will soon be approved in China.
-
One of the special uses of EPO: to check the Chinese name of Japanese pharmaceutical enterprises by Romanized alphabet
Time of Update: 2017-11-27
Similar methods can be used to translate the names of Japanese patent inventors into Chinese characters from Roman Pinyin.
-
EPO market broke out under domestic monopoly or exceeded 10 billion!
Time of Update: 2017-09-13
Source: pharmaceutical economic report 2017-09-13 erythropoietin (hereinafter referred to as EPO) is the abbreviation of "erythropoietin", which is a kind of glycoprotein
-
In depth report: recombinant protein drugs, EPO market under domestic monopoly
Time of Update: 2014-10-22
There are many patients with chronic kidney disease and cancer in China
Erythropoietin (EPO) is the most important hematopoietic growth factor for the proliferation
-
Recombinant protein drugs, EPO market under domestic monopoly
Time of Update: 2014-10-22
In June 1989, Amgen company successfully developed and launched the world's first recombinant human erythropoietin (rhEPO) product, Epogen (afaepatin), mainly in the treatment of renal anemia, anemia caused by radiotherapy and chemotherapy of malignant tumors and other symptoms.
-
Recombinant protein drugs, EPO market under domestic monopoly
Time of Update: 2014-10-22
In June 1989, Amgen company successfully developed and launched the world's first recombinant human erythropoietin (rhEPO) product, Epogen (afaepatin), mainly in the treatment of renal anemia, anemia caused by radiotherapy and chemotherapy of malignant tumors and other symptoms.
-
African equine disease in South Africa (6.1)
Time of Update: 2003-03-12
VXF date of report: May 26, 2000 VXF nature of diagnosis: clinical and laboratory VXF date of initial discovery: May 18, 2000 VXF incidence: incidence of VXF location Ibaraki District, makabe City 1 Situation of diseased animals: commercial broiler farm.
